Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.
James Chih-Hsin YangCaicun ZhouPasi A JänneSuresh S RamalingamTae Min KimGregory J RielyAlexander I SpiraZofia PiotrowskaTarek MekhailMaria Rosario Garcia CampeloEnriqueta FelipLyudmila BazhenovaShu JinManmit KaurPaul M DiderichsenNeeraj GuptaVeronica BunnJianchang LinEric N ChurchillMinal MehtaDanny NguyenPublished in: Expert review of anticancer therapy (2022)
NCT02716116; NCT03807778.